Johnson & Johnson (JNJ) announced that the European Commission (EC) has approved its lung cancer drug Rybrevant (amivantamab) for expanded use.The EC approved a type II extension of indication for Rybrevant in combination with chemotherapy (carboplatin and pemetrexed) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions after failure of prior therapy, including an EGFR tyrosine kinase inhibitor (TKI).JNJ's Stock PerformanceShares of JNJ have increa ...